1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose

K. Park; J. S. Lee; J. Y. Han; K. H. Lee; J. H. Kim; E. K. Cho; J. Y. Cho; Y. J. Min; J. S. Kim; D. W. Kim

doi:10.1016/S1556-0864(16)30243-X

1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose

K. Park, J. S. Lee, J. Y. Han, K. H. Lee, J. H. Kim, E. K. Cho, J. Y. Cho, Y. J. Min, J. S. Kim, D. W. Kim

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	S113
Journal	Journal of Thoracic Oncology
Volume	11
Issue number	4
DOIs	https://doi.org/10.1016/S1556-0864(16)30243-X
State	Published - Apr 2016

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine

Access to Document

10.1016/S1556-0864(16)30243-X

Cite this

@article{4cf54fa7c22a407899f0854791f2caaa,

title = "1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose",

author = "K. Park and Lee, {J. S.} and Han, {J. Y.} and Lee, {K. H.} and Kim, {J. H.} and Cho, {E. K.} and Cho, {J. Y.} and Min, {Y. J.} and Kim, {J. S.} and Kim, {D. W.}",

year = "2016",

month = apr,

doi = "10.1016/S1556-0864(16)30243-X",

language = "English (US)",

volume = "11",

pages = "S113",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "International Association for the Study of Lung Cancer",

number = "4",

}

TY - JOUR

T1 - 1300

T2 - Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose

AU - Park, K.

AU - Lee, J. S.

AU - Han, J. Y.

AU - Lee, K. H.

AU - Kim, J. H.

AU - Cho, E. K.

AU - Cho, J. Y.

AU - Min, Y. J.

AU - Kim, J. S.

AU - Kim, D. W.

PY - 2016/4

Y1 - 2016/4

UR - http://www.scopus.com/inward/record.url?scp=84992503694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992503694&partnerID=8YFLogxK

U2 - 10.1016/S1556-0864(16)30243-X

DO - 10.1016/S1556-0864(16)30243-X

M3 - Article

AN - SCOPUS:84992503694

SN - 1556-0864

VL - 11

SP - S113

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 4

ER -

1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this